drugset / Trial / NCT00525512

Tiotropium In Exercise

NCT00525512

Phase 4 Completed 519 enrolled Boehringer Ingelheim Pfizer · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the effects on exercise duration of 96 weeks treatment with 18 mcg tiotropium (Spiriva HandiHaler) daily as compared to placebo, in patients with COPD.

Timeline

Start
2007-08
Primary completion
2010-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 18 ug Inhaled